Evidence map›Paper›PMID 35552670›Full record

ArticleEndocrinology2022

Intestinal Enteroendocrine Cell Signaling: Retinol-binding Protein 2 and Retinoid Actions.

Rossana M Calderon, Christopher A Smith, Emily L Miedzybrodzka, Josie A Silvaroli, Marcin Golczak, Fiona M Gribble, Frank Reimann, William S Blaner

Open access · bronzeAbstract read
In one paragraph

Article in Endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Rossana M CalderonDepartment of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.ORCID 0000-0001-7403-2441
Christopher A SmithInstitute of Metabolic Sciences and MRC-Metabolic Diseases Unit, University of Cambridge, Cambridge CB0 0QQ 44106, UK.
Emily L MiedzybrodzkaInstitute of Metabolic Sciences and MRC-Metabolic Diseases Unit, University of Cambridge, Cambridge CB0 0QQ 44106, UK.
Josie A SilvaroliDepartment of Pharmacology, Case Western Reserve University, Cleveland, OH, USA.
Marcin GolczakDepartment of Pharmacology, Case Western Reserve University, Cleveland, OH, USA.
Fiona M GribbleInstitute of Metabolic Sciences and MRC-Metabolic Diseases Unit, University of Cambridge, Cambridge CB0 0QQ 44106, UK.
Frank ReimannInstitute of Metabolic Sciences and MRC-Metabolic Diseases Unit, University of Cambridge, Cambridge CB0 0QQ 44106, UK.
William S BlanerDepartment of Medicine, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
University of Cambridge · GBCase Western Reserve University · USColumbia University · US

Funding

POSTDOCTORAL TRAINING IN ARTERIOSCLEROSIS RESEARCHT32HL007343 · NHLBI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI HENRY N GINSBERG, Muredach P Reilly · 1985 to 2026
$12.7M
The Organoid and Cell Culture CoreP30DK132710 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Robert F. Schwabe · 2022 to 2026
$7.2M
Postprandial Vitamin AR01DK068437 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BLANER, WILLIAM S · 2004 to 2023
$7.0M
RBP2 Biology and PathobiologyR01DK122071 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI WILLIAM S BLANER, Marcin Bernard Golczak · 2019 to 2026
$4.6M
Alcohol, Retinoids and Pancreas BiologyR21AA028110 · NIAAA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BLANER, WILLIAM S · 2019 to 2020
$425k
Medical Research Council MC_UU_00014/3Medical Research Council MC_UU_00014/5Medical Research Council MC_UU_12012/3Medical Research Council MC_UU_12012/5NHLBI NIH HHS T32 HL007343NIAAA NIH HHS R21 AA028110NIDDK NIH HHS P30 DK132710NIDDK NIH HHS R01 DK068437NIDDK NIH HHS R01 DK122071Wellcome Trust 220271
6 · The paper itself

Abstract

Retinol-binding protein 2-deficient (Rbp2-/-) mice are more prone to obesity, glucose intolerance, and hepatic steatosis than matched controls. Glucose-dependent insulinotropic polypeptide (GIP) blood levels are dysregulated in these mice. The present studies provide new insights into these observations. Single cell transcriptomic and immunohistochemical studies establish that RBP2 is highly expressed in enteroendocrine cells (EECs) that produce incretins, either GIP or glucagon-like peptide-1. EECs also express an enzyme needed for all-trans-retinoic acid (ATRA) synthesis, aldehyde dehydrogenase 1 family member A1, and retinoic acid receptor-alpha, which mediates ATRA-dependent transcription. Total and GIP-positive EECs are significantly lower in Rbp2-/- mice. The plasma transport protein for retinol, retinol-binding protein 4 (RBP4) is also expressed in EECs and is cosecreted with GIP upon stimulation. Collectively, our data support direct roles for RBP2 and ATRA in cellular processes that give rise to GIP-producing EECs and roles for RBP2 and RBP4 within EECs that facilitate hormone storage and secretion.

Indexed as

Enteroendocrine CellsRetinoidsAnimalsGastric Inhibitory PolypeptideGlucagon-Like Peptide 1MiceReceptors, G-Protein-CoupledRetinol-Binding Proteins, CellularGastric Inhibitory PolypeptideGlucagon-Like Peptide 1Receptors, G-Protein-CoupledRetinoidsRetinol-Binding Proteins, Cellularenteroendocrine cellsglucagon-like peptide-1glucose-dependent insulinotropic polypeptideincretinsretinoidsretinol-binding protein 2

Identifiers

PMID35552670
PMCPMC9162388
OpenAlexW4280617010

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.